Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.

@article{Pasanen1995TumourassociatedTI,
  title={Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.},
  author={Pentti A. Pasanen and Matti Eskelinen and Arto Kulju and Ilkka M Penttil{\"a} and Esko Janatuinen and Esko M. Alhava},
  journal={Scandinavian journal of clinical and laboratory investigation},
  year={1995},
  volume={55 2},
  pages={119-24}
}
A prospective study of 62 patients with colorectal cancer was carried out to evaluate the value of tumour-associated trypsin inhibitor (TATI) in the diagnosis and staging of this disease. The reference group consisted of 97 patients with benign gastrointestinal disease. Increased serum TATI levels were detected in 46 patients with colorectal cancer (sensitivity 74%), and the highest mean values were measured in the patients with stage II cancer. The frequency of elevated values was not affected… CONTINUE READING